PAREXEL enhances its Regulatory Cloud;
leverages EMC® Documentum® for Life Sciences software solution
suite to offer an end-to-end regulatory solution
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services organization, and EMC Corporation
(NYSE: EMC) today announced they have entered into an alliance to
offer an end-to-end Regulatory Information Management (RIM) and
Regulatory Content Management solution.
By combining PAREXEL® LIQUENT InSight® Regulatory Information
Management platform and EMC® Documentum® for Life Sciences software
solution suite, PAREXEL now provides life sciences companies with a
complete solution for a product’s entire regulatory lifespan. Life
science companies can utilize the solution for strategy and
planning, authoring, publishing, submitting, viewing, archiving,
and lifecycle management for a product. The offering is available
through PAREXEL’s Regulatory Cloud, a life sciences content and
regulatory information management solution structured within a
dedicated, private cloud environment.
“A life sciences company must navigate the complex, global and
region-specific regulatory landscape to maintain registration and
compliance for a product,” said Paul Bidez, Ph.D., Vice President
and Global Head of Regulatory Solutions, PAREXEL. “To help solve
this challenge for our clients, PAREXEL and EMC brought together
our respective industry-leading regulatory information management
platform and industry-leading life sciences content management
solution suite within PAREXEL’s Regulatory Cloud.”
PAREXEL’s Regulatory Cloud utilizes identity-based security that
ensures that only authorized users can gain access to the
infrastructure and application resources they require. Applications
can be configured or integrated to meet client-specific
requirements.
The EMC Documentum for Life Sciences software solution suite can
eliminate companies’ data silos to transform how organizations
access, manage and share information across nonclinical, clinical,
quality and regulatory groups, ensuring a single, authoritative
source for regulated content. The fully-integrated suite leverages
industry standards and utilizes easily configurable, intuitive, and
personalized interfaces to maximize productivity and ensure easy
access to information. This helps to bring high-quality and safer
drugs to market faster, improving health and well-being, while
lowering costs.
“Industry pressures are prompting biopharmaceutical
organizations to adopt new business models, enter new global
markets, and expand alliances and partnerships. To achieve these
goals, Life Sciences organizations are becoming more strategic in
how they manage information,” said Rohit Ghai, President,
Enterprise Content Division, EMC. “By partnering with PAREXEL,
we’re enabling these organizations to digitally transform and
deliver high-quality, safer drugs to market faster and at a lower
cost, while meeting regulatory requirements.”
Regulatory Cloud is offered by PAREXEL directly or through the
Company's Perceptive® Partner Program.
About LIQUENT InSightSince the market introduction of
LIQUENT InSight in 2004, 16 of the top 20 pharmaceutical companies
have selected the LIQUENT InSight platform as their authoritative
source of regulatory information. PAREXEL’s RIM technologies can
also be coupled with comprehensive professional services from
PAREXEL, which provides a full complement of Regulatory Outsourcing
Services to help companies meet the demands of today’s complex and
changing regulatory environment.
About EMC Documentum for Life Sciences software solution
suiteOver 75% of leading life sciences firms rely on EMC
Documentum. Our tightly integrated solutions deliver standardized
business processes that simplify access to content. The EMC
Documentum for Life Sciences software solution suite delivers
proactive, automated, business rules and enhancements across the
suite while ensuring a simple, user experience to reduce risk,
streamline processes and boost worker productivity. Organizations
can create a single authoritative source for regulated content,
seamlessly link and share content across departments (or divisions)
and provide proactive notifications to document authors, owners and
users when document changes take place or actions and tasks are
required. The suite includes: EMC Documentum Electronic Trial
Master File, EMC Documentum Research and Development, EMC
Documentum Submission Store and View, and EMC Documentum Quality
and Manufacturing.
About EMCEMC Corporation is a global leader in enabling
businesses and service providers to transform their operations and
deliver IT as a service. Fundamental to this transformation
is cloud computing. Through innovative products and services,
EMC accelerates the journey to cloud computing, helping IT
departments to store, manage, protect and analyze their most
valuable asset — information — in a more agile, trusted and
cost-efficient way. Additional information about EMC can be found
at www.EMC.com.
EMC and Documentum are registered trademarks or trademarks of
EMC Corporation in the United States and other countries. All other
trademarks used herein are the property of their respective
owners.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of expertise-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston, Massachusetts, PAREXEL has offices in 77
locations in 51 countries around the world and had approximately
18,200 employees in the second quarter. For more information about
PAREXEL International, visit www.PAREXEL.com.
PAREXEL is a registered trademark of PAREXEL International
Corporation. All other trademarks are the property of their
respective owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160413005544/en/
PAREXEL:Cristi
Barnett+1-781-434-4019Cristi.Barnett@PAREXEL.comorEMC:Jeff
Neal+1-510-246-2384Jeffrey.Neal@EMC.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Sep 2023 to Sep 2024